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Abstract
Type 2 diabetes has a global prevalence, with epidemiological data suggesting that some populations have a higher risk of
developing this disease. However, to date, most genetic studies of type 2 diabetes and related glycaemic traits have been
performed in individuals of European ancestry. The same is true for most other complex diseases, largely due to use of
‘convenience samples’. Rapid genotyping of large population cohorts and case–control studies from existing collections was
performed when the genome-wide association study (GWAS) ‘revolution’ began, back in 2005. Although global representation
has increased in the intervening 15 years, further expansion and inclusion of diverse populations in genetic and genomic studies is
still needed. In this review, I discuss the progress made in incorporating multi-ancestry participants in genetic analyses of type 2
diabetes and related glycaemic traits, and associated opportunities and challenges. I also discuss how increased representation of
global diversity in genetic and genomic studies is required to fulfil the promise of precision medicine for all.
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Introduction
Type 2 diabetes is a multifactorial disease where a combina-
tion of genes, lifestyle and environment contribute to disease
predisposition worldwide. The IDF projected that by 2045,
700 million people worldwide would have diabetes, with
low- and middle-income countries accounting for the largest
increases in prevalence [1].
Since 2005, with the advent of genome-wide association stud-
ies (GWAS), the number of genetic loci known to influence type
2 diabetes risk and/or related quantitative glycaemic measures
(e.g. glucose, insulin, HbA1c levels) has surged. To date, more
than 270 loci (with >400 signals) associated with type 2 diabetes
risk and/or glycaemic traits have been identified mostly through
meta-analysis of existing GWAS [2–6]. Despite this success,
most type 2 diabetes GWAS do not represent the diversity of
affected individuals as they have focused on individuals of
European ancestry [7, 8] and, more recently, East Asian ancestry
[2, 3]. This means we are still missing important aetiological
factors that may differ among diverse global populations and
consequently we may be increasing health disparities. In
healthcare, sociocultural self-reported ethnicity or ‘race’ are often
used as proxies for genetic ancestry. This is particularly problem-
atic, as these proxies are confounded by socioeconomic status
and cultural and lifestyle factors, and do not consider the genetic
heterogeneity between individuals of the same self-reported
ethnicity [9]. Different self-reported ethnic groups overlap genet-
ically and two individuals of the same self-reported ethnicitymay
be genetically more ‘distant’ from one another than two individ-
uals that each identify with a different ethnic group. This review
aims to highlight the opportunities and challenges of including
datasets from a broad range of population ancestries in genetic
studies of type 2 diabetes and related traits. It also discusses how
increasing diversity in genetic studies may impact on precision
medicine in type 2 diabetes.
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GWAS from diverse populations
The lack of diversity in GWAS has been well document-
ed [10–13] and has spurred new efforts to increase global
representation, including the Human Health and
Hereditary initiative in Africa [14], the All of Us
programme in the USA [15] and new initiatives such as
the ‘Latin American Alliance for Genomic Diversity’
(International Common Disease Alliance [ICDA], plena-
ry programme 2020), the Taiwan precision medicine
initiative [16] and The Brazilian Initiative on Precision
Medicine (BIPMed) [17].
Allelic frequency differences between populations aid locus
discovery GWAS in diverse populations has facilitated the
discovery of novel type 2 diabetes aetiological factors owing
to their divergent allele frequency across populations. One
example is the risk haplotype near SLC16A11, discovered in
Mexicans, that has high frequency in populations from the
Americas (~50%), intermediate frequency in East Asians
Allelic heterogeneity The process through which different mutations at the same locus can lead to the same 
phenotype. It also describes the situation in which different variants can underlie the effect of a given locus 
on a phenotype, in particular when referring to the possibility of the existence of causal variants at the same 
locus that differ between ancestries
Clumping Grouping together variants that represent the same ‘effect’ into a locus associated with a pheno-
type. Clumping is normally done by linkage disequilibrium (LD) and/or distance to the lead variant. Distance-
based clumping normally groups together all variants within a particular region (e.g. a 500 Kb–1 Mb region), 
centred on the lead variant
Fine-mapping The process through which researchers attempt to resolve association signals into a smaller 
set of variants most likely to be causal
Genetic risk score (GRS) A genetic score that is built on the basis of variants associated with a phenotype 
at genome-wide significant levels. Each variant is weighted by its effect size on disease risk
Genome-wide association study (GWAS) An approach that tests, in a single experiment, thousands to 
millions of genetic variants for association with a phenotype, which can be a disease or continuous trait
Lead variant The variant in a locus associated with the phenotype with the most significant p value
Linkage disequilibrium (LD) A measure of the correlation of genetic variants with each other in the genome. 
Due to differences in population history and demography, LD varies between populations
Meta-analysis A statistical approach that allows data from different studies to be combined to increase 
power. This approach is commonly used to combine GWAS datasets from multiple cohorts to increase power 
for locus discovery. Combining data across different studies normally relies on the availability of genotype 
data for the same variants in all studies so as to maximise the data without too many missing values. Usually, 
this requires imputation of variants not directly assayed in the genotyping array used
Imputation A statistical approach that allows the estimation of genotypes at variants not directly as-
sayed. This requires the use of an imputation reference panel that contains genotype data across mil-
lions of variants and allows the correlation structure, or LD structure, in the relevant reference popula-
tion to be used to estimate the missing genotypes in the desired population
Partitioned genetic scores Genetic scores that are built on a subset of variants in a GRS that have been 
subgrouped based on their inferred effect on different pathways linked to a disease. Thus, the GRS is parti-
tioned into subgroups
Polygenic risk score (PRS) Similar to a genetic score but built instead on the basis of thousands to millions 
of variants in the genome associated with a disease or trait at a more liberal p value threshold than genome-
wide significance
Winner’s curse An ascertainment bias where the genetic effect size is overestimated within the discovery 
dataset
Glossary of terms 
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(~10%) and is rare or absent in populations from Europe and
Africa [18]. Other examples include the rare Glu508Lys vari-
ant inHNF1A identified in Latinos that increases type 2 diabe-
tes risk fivefold [19] and the East Asian Arg193His PAX4
variant [20].
The largest analyses of type 2 diabetes in African
Americans to date identified novel African American signals
at HLA-B and INS-IGF2 loci [21]. GWAS of cardiometabolic
traits including African participants are still few [22–26] but
further highlight a type 2 diabetes risk variant at ZRANB3,
which is monomorphic elsewhere [24], and new African
signals at TCF7L2 (rs17746147) and near AGMO
(rs73284431 [23]). A pan-African GWAS of 34 cardiometa-
bolic traits that included 14,126 individuals identified a vari-
ant driven by the α−3.7 thalassaemia deletion associated with
HbA1c in Ugandans [25]. This deletion is more frequent in
Ugandans as it confers resistance to severe malaria, which is
endemic in Uganda [25].
These are important examples of population-specific
signals (i.e. signals where the variant is very rare or mono-
morphic outside the cognate population, or signals where
the effect of the variant on the trait has not been observed
outside those cognate populations). Nonetheless, they can
reveal population-specific disease aetiology, provide novel
insights into pathophysiological pathways involved in
disease and highlight novel aspects of biology not previ-
ously understood.
Population-specific signals may be clinically important
Population-specific signals can identify variants that have
large effects in cognate populations and, hence, may have
an important translational impact in those populations. For
example, the TBC1D4 nonsense variant p.Arg684ter was
initially found in Inuits from Greenland [27], where it has a
high prevalence (17%) and large effect size (homozygous
carriers have an approximately tenfold increased risk of
type 2 diabetes), but is very rare or absent elsewhere. The
same variant has now been detected at high frequency
(~13–16% minor allele frequency) in North American
Inuit populations. Here, it was shown that unless postpran-
dial glucose levels were tested, 32% of TBC1D4
p.Arg684ter carriers with prediabetes (defined as fasting
plasma glucose 5.6–6.9 mmol/l, 2 h 75 g OGTT plasma
glucose 7.8–11.0 mmol/l and/or HbA1c 5.7–6.4% [39–
46 mmol/mol]) and diabetes would remain undiagnosed
[28]. In light of increasing diabetes prevalence in the
Inuit [29], it has been suggested that stratifying diabetes
diagnoses based on an individual’s TBC1D4 p.Arg684ter
genotype, and performing OGTTs in carriers of this vari-
ant, may be appropriate in this population [28]. In addition,
TBC1D4 acts on the insulin-stimulated glucose response
pathway so it is plausible that carriers for this variant will
have improved response to insulin sensitisers, although
clinical trials have yet to be performed to test this [28].
On the other hand, a recent longitudinal analysis of Inuits
in Greenland suggested that homozygosity for TBC1D4
p.Arg684ter did not significantly increase risk of incident
CVD in this population [30]. Given the small number of
homozygous TBC1D4 p.Arg684ter individuals in the study
(n = 142), the possible inaccuracy in defining CVD
outcomes, insufficient number of follow-up years, or other
factors discussed by the authors [30], it is critical to repli-
cate this finding. If replicated, this could suggest that
diabetes associated with homozygosity for TBC1D4
p.Arg684ter is similar to MODY due to GCK mutations
[31], and would impact on how diabetes is managed in
individuals homozygous for TBC1D4 p.Arg684ter.
Overall, this example highlights the potential importance
of capturing population-specific signals for precision
medicine approaches in diabetes diagnosis.
Interpreting population-specific signals can be challenging
Establishing the broader relevance and reproducibility of
population-specific signals, especially those that result
from sequence-based rare variant analysis, can be difficult.
This is because due to founder effects, drift and selection,
population isolates are enriched for alleles that may be very
rare or absent elsewhere [32]. In addition, some indigenous
specific variants originate from discovery sample sizes in
the order of thousands rather than hundreds of thousands
and large population resources for replication are not
always readily available. Naturally, larger effect sizes in
these population-specific signals are not uncommon, as
these are the effect sizes some of these smaller discovery
samples are well-powered to detect. In these scenarios,
given the high multiple testing burden, the lower power
and the absence of replication datasets, it can be hard to




Recently, efforts to jointly analyse different genetic datasets
from populations of diverse ancestry have becomemore wide-
spread [5, 6]. These multi-ancestry genetic analyses boost
power for new locus discovery, provide the opportunity to test
for widespread replication of signals across independent
populations and allow exploration of the genetic architecture
of phenotypes across ancestries.
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Portability of signals across populations Evidence to date
suggests that most common variants associated with type 2
diabetes or continuous glycaemic traits are shared and have
broadly equivalent effects across ancestries [6, 33]. However,
the Population Architecture using Genomics and Epidemiology
(PAGE) Consortium showed significant effect size attenuation at
established loci in non-Europeans. As effect sizes were differen-
tially attenuated between ancestries (by ~56% in African
Americans and ~24% in Hispanics/Latinos), this suggested the
attenuation was not just due to ‘winner’s curse’ [34]. Recently, in
a large multi-ancestry meta-analysis, we also found evidence of
effect size heterogeneity between populations, in approximately
20%of loci associatedwith glycaemic traits [6]. For example, we
detected significant evidence of effect allele heterogeneity at
fasting glucose lead variants between European and East Asian
ancestry participants (Fig. 1a). In addition, we found novel loci
that had broadly similar allele frequency but with significant
effect size differences across ancestries and evidence of associa-
tion at single ancestries. The variant rs61909476, near ETS1, is
associated with fasting glucose in African American individuals
but not in those from any of the other ancestries, despite broadly
similar allele frequency across ancestries (Fig. 1b) [6]. Effect size
differences between ancestries can occur because the variant is
tagging a causal variant more strongly in one ancestry or because
there are population-specific genetic epistatic effects (i.e.
genotype-by-genotype interactions) or genotype-by-
environment interactions.
Benefits and challenges of multi-ancestry studies Multi-
ancestry approaches have improved global representation,
vastly increased the total sample size of type 2 diabetes and
related quantitative trait genetic studies, and have yielded
additional associated loci that have effects across populations
from multiple ancestries. Often the variant identified from
combined multi-ancestry analysis does not meet stringent
genome-wide significance thresholds in individual contribut-
ing ancestries but there is still evidence that it captures a
proportion of the heritability of that trait in that ancestry
(Fig. 2) [2, 4–6]. Specifically, a recent study by the Meta-
Analysis of Glucose and Insulin-related traits Consortium
(MAGIC), which included 30% non-European ancestry
participants, showed that including lead variants identified
from the meta-analysis across ancestries in a genetic score
captured more of the trait variance than the more limited set
of variants that met stringent genome-wide significant thresh-
olds in that population (Fig. 2) [6].
Challenges of genetic meta-analyses across ancestries
relate to differences in linkage disequilibrium (LD) between
populations of diverse ancestry. In this setting, clumping of
variants into loci cannot be done by LD but rather by grouping
together variants based on a predefined distance to the lead
variant. One of the challenges of combining diverse popula-
tion data is that the lead variant can vary between ancestries.
Interpreting this can be difficult as it could result from random
fluctuation (e.g. slightly different samples with good quality
Fig. 1 Fasting glucose lead variants with evidence of effect allele
heterogeneity across populations of different ancestry. (a) Fasting
glucose-associated lead variants were tested for evidence of effect allele
heterogeneity between populations. The findings from the test of effect
allele heterogeneity are shown; a one-side heterogeneity test without
multiple testing corrections was conducted and different shades of blue
represent different p value thresholds (the darker the shade of blue, the
more significant the p value). *p<1×10−4 to ≤0.05; **p<1 ×10−6 to
≤1×10−4; ***p≤1×10−6 (dash [–] represents p>0.05). (b) Forest plot
showing the effect allele frequency, effect size, 95% CIs and p value
for rs61909476, the lead variant associated with fasting glucose in partic-
ipants of African American ancestry. The same variant shows no
evidence of association with fasting glucose in the other ancestries includ-
ed in the analyses. AA, African American ancestry; EAF, effect allele
frequency; EAS, East Asian ancestry; EUR, European ancestry; HISP,
Hispanic ancestry; SAS, South Asian ancestry. Adapted from [6]. This
figure is available as part of a downloadable slideset
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genotype data at each variant) or different tagging of the
underlying causal variant, or it could reflect allelic
heterogeneity.
Fine-mapping The high degree of LD in European popula-
tions is both an advantage and disadvantage when conducting
GWAS. High LD between variants is beneficial when
conducting locus discovery as many correlated variants can
point to a strong association signal. However, a consequence
of this is that many variants are indistinguishable from one
another in terms of their association with a disease/trait and it
can therefore be difficult to establish which is the variant(s)
driving the association (causal variant[s]). Fine-mapping is
improved through increasing sample size so that LD can be
‘broken’ and smaller sets of variants can be identified. An
approach which has gained interest is the use of populations
of diverse ancestry to refine association signals [35]. Given
that the LD structure differs between populations of different
ancestry, this can be leveraged to refine association signals
and reduce the number of variants that need to be considered
as possibly causal. This has facilitated researchers in resolving
association signals to identify a smaller number of likely caus-
al variants that can more reasonably be experimentally tested
for functional effects [5, 6, 35–37].
However, fine-mapping across ancestries assumes no alle-
lic heterogeneity at the locus being fine-mapped and assumes
the causal variant(s) is shared across all populations used.
Consequently, where there is true allelic heterogeneity fine-
mapping across ancestries may fail. In addition, there may be
technical challenges as many methods relying on summary
statistics require that all variants used in the fine-mapping step
have data from broadly similar sample sizes, otherwise they
may identify false-positive causal variants. Moreover, remov-
al of variants due to quality control issues could inadvertently
remove the true causal variant. Nonetheless, fine-mapping
methods may still identify a set of variants with high proba-
bility of being causal, which may lead researchers to follow an
incorrect set of variants in downstream analyses. Comparing
results from the fine-mapping to the original meta-analysis
within and across ancestries is therefore key to ensure that
the lead variant(s), for example, are still within the set of likely
causal variants after fine-mapping. Fine-mapping across
ancestries can also be challenging, as many methods are not
able to account for the heterogeneity in LD across ancestries.
An important challenge is that different fine-mapping
methods will yield different results so, ultimately, functional
validation is required to validate causal variants. Finally,
phenotype heterogeneity could also underlie some differences
across populations. This is less pertinent to quantitative trait
measures that are well standardised but can complicate inter-
pretation in disease studies if cases are ascertained based on
very different criteria.
The importance of conducting studies
across multiple ancestries for precision
medicine
In contrast to existing approaches to medicine that have been
described as ‘one size fits all’, precision medicine proposes to
take into account individual differences in genetic makeup,
environment and lifestyle when considering disease presenta-
tion, diagnoses, treatment and prevention [38].
Historically, there has been limited representation of indi-
viduals of diverse ancestry in biobanks, in clinical trials [39]
and, as discussed earlier, in genetic studies. Lack of represen-
tation in studies means that diagnostic thresholds, treatment
regimens and prediction models do not consider genetic
Fig. 2 Variance in fasting glucose explained by associated fasting
glucose loci. The box and whisker plot shows the trait variance (r2)
explained when using a genetic score with variants that are associated
with fasting glucose at genome-wide significant thresholds in each indi-
vidual ancestry (European [EUR;], East Asian [EAS;], Hispanic [HISP;],
African American [AA;] or Southeast Asian [SAS;]), or when using a
combination of lead variants identified by meta-analysis across all partic-
ipating ancestries (trans-ancestry [TA]) and individual ancestry genome-
wide associated variants (TA+EUR, TA+EAS, TA+HISP, TA+AA and
TA+SAS). Variance in fasting glucose explained by each of the variant
lists in each individual ancestry is shown in blue (EUR), purple (EAS),
red (HISP), orange (AA) and grey (SAS). The line within each box
represents the median, and the top and bottom of the box represent the
first and third quartile, respectively. The whiskers indicate the maximum
and minimum values. Data points represent the variance explained in
individual cohorts used in the analysis. Figure from [6]. This figure is
available as part of a downloadable slideset
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differences between ancestries. This means that most of the
health and economic benefit from genetics-driven approaches
to medicine will inequitably benefit higher income countries
(and within those, individuals of European descent), increas-
ing health disparities between diverse populations [40].
Impact of individual variants on diagnosis, treatment
response and adverse drug reactions In addition to the
TBC1D4 nonsense mutation, discussed above, which may
have important implications for diabetes diagnosis in Inuit
populations, there are other examples of ancestry-
differentiated variants with impact on type 2 diabetes diagno-
sis and treatment.
The G6PD Val98Met (rs1050828) variant causes
glucose 6-phosphate dehydrogenase deficiency, a
haemolytic anaemia that is often silent in carriers (i.e. they
may not know they have the mutation). The same variant
reduces HbA1c levels (β = −0.81% [95% CI 0.66, 0.96]
per minor allele) independently of glucose levels and
potentially leads to under-diagnoses of diabetes in carriers
[41, 42]. Other G6PD variants that lower HbA1c levels
have been identified in Hispanic/Latino [43] and Asian
populations [44]. In addition, carriers of the α−3.7 thalasse-
mia deletion [25] and asymptomatic individuals with sickle
cell trait (rs334 Glu7Val) [43, 45] all have reduced HbA1c
levels, independent of glucose levels.
Some of the above variants are common (minor allele
frequency >10%) in populations with endemic malaria,
as they provide protection against severe malaria
[46–48], and all affect the utility of HbA1c as a diagnos-
tic test for diabetes in those populations. Because the
prevalence of these variants differs between ancestral
groups, ignoring genotype at these variants could exac-
erbate health disparities. In addition, in carriers being
treated for diabetes, physicians may overestimate the
degree of glucose control (as carriers will have dispro-
portionately low HbA1c for their blood glucose levels)
and therefore undertreat [44].
Beyond effects on diagnosis and treatment targets, the
G6PD Val98Met variant is associated with significant risk
of haemolysis in women treated with the antimalarial agent
primaquine [49] and the US Food and Drug Administration
has declared the need to consider G6PD status for patients
prescribed certain sulfonylureas [50], highlighting the impor-
tance of knowing genotype at this site before prescribing
drugs.
The promise of genetic risk scores Variants that associate at
genome-wide significant levels with a trait or a disease can be
used to construct genetic risk scores (GRSs) that explain or
predict a certain proportion of the trait variance in the
population [51, 52]. The hope is that these scores may have
clinical utility by facilitating identification of individuals at
higher risk of disease, aiding in differential diagnoses, better
targeting of treatment and therapy dosage to patients, and
helping to avoid adverse drug reactions.
Early type 2 diabetes GRSs were built on a limited set of
variants, explained a relatively modest fraction of phenotypic
variance and were not very useful for disease prediction
[53–56]. Additionally, as they were mostly built on results
from large meta-analyses of European ancestry GWAS, they
missed the effects of other ancestry-specific trait-associated
variants, namely variants under different types of selection
in populations exposed to different environments.
Furthermore, the effect size estimates used were overinflated
due to ‘winner’s curse’ in discovery studies [57].
However, as sample sizes increased, more variants have
been detected that capture more of trait variance. In addition,
when genome-wide associated variants from multi-ancestry
studies are used to build GRSs, they capture a larger fraction
of phenotypic variance than ancestry-specific GRSs even if
the variants are not associated with the disease at genome-
wide significance level in all ancestries [5, 6, 58]. This
suggests that such multi-ancestry efforts may be required for
GRSs to be more globally transferable.
A type 1 diabetes GRS with clinical utility Provision of the
correct diabetes diagnosis is important, as the optimal treat-
ment is different for type 1 diabetes, type 2 diabetes and other
rare monogenic forms of diabetes. Here, a type 1 diabetes
GRS (and subsequent successor) has clinical utility, improv-
ing newborn screening and supporting classification of adult
incident diabetes in individuals of European ancestry [59, 60].
It also helps differentiate between type 1 diabetes and mono-
genic neonatal diabetes or MODY [61] and monogenic auto-
immune diabetes [62]. Despite early concerns regarding the
transferability of the GRS to other ancestries [59], the GRS
was shown to discriminate between monogenic and type 1
diabetes in Iranian children [63]. It also discriminates between
type 1 and type 2 diabetes in India, where misclassification of
type 1 diabetes and type 2 diabetes is common in young adults
due to the high prevalence of early-onset type 2 diabetes at
lower BMI [64].
Polygenic risk scores Beyond genome-wide significant variants,
models that include additional loci in the genome that have not
reached this stringent threshold capture a larger fraction of trait
variance [65–67]. These variants have been included in polygen-
ic risk scores (PRSs), which are built on a large number of vari-
ants in the genome (in the order of thousands to several million),
to improve disease prediction [68–70] (see Text box: Concerns
regarding transferability of PRSs).
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A proposed potential benefit of PRSs is their ability to
identify high-risk individuals from birth before classical clin-
ical and biomarker risk factors can be detected, thus enabling
identification of a subset of the population who would most
benefit from careful screening andmonitoring, and from being
placed on available preventative strategies or therapies [56].
They may also identify individuals at much larger risk of
disease who might not display classical clinical risk factors
and would, hence, be missed by current approaches [56],
though this has been questioned [71].
Individuals at the top end of the distribution for type 2
diabetes PRSs have a disease risk similar to that of individuals
harbouring some monogenic mutations [8, 56]. Nevertheless,
concerns regarding portability of these scores across popula-
tions (see Text box: Concerns regarding transferability of
PRSs) raise doubt over their current clinical utility, and
provide a compelling argument for developing scores based
on discovery data from diverse populations, as these more
readily transfer from discovery to different target populations
[57, 58]. Given these concerns, at least for type 1 and type 2
diabetes, it has been suggested by some that GRSs (especially
those arising from multi-ancestry analyses) may be currently
preferable, as the additional variants in the PRS do not signif-
icantly improve the performance of these scores for clinical
use [71, 72].
Beyond the cross-population transferability issues that may
or may not be addressed by further methodological develop-
ment, questions remain regarding how PRSs predict disease
risk across the lifespan [73, 74], how risk is understood and
communicated by practicing clinicians to their patients and,
more generally, how to incorporate their use into routine clin-
ical practice [75]. Indeed, the debate rages on as to whether
these scores will provide broad clinical utility beyond a few
examples [68, 71, 76, 77].
Partitioned genetic scores In addition to the use of GRSs and
PRSs for disease classification and prediction, the develop-
ment of partitioned genetic scores corresponding to variants
predicted to affect disease through different physiological
pathways has gained interest as a means to acquire insight into
Over the years, different methods and associated software packages have been developed to derive PRSs
[87-90]. These require developing the PRS based on one dataset, validating it in an independent dataset, 
and finally applying it to the desired target population. 
These methods use different algorithms to select the best combination of SNPs across the entire genome 
that maximise the phenotypic variance explained. Or, in other words, it selects the combination of SNPs that 
best captures phenotype variation in that population.
To work, these methods have to account for the LD between SNPs so they do not ‘double count’ effects of 
highly correlated SNPs (SNPs with highly correlated effects). The challenge is that, when using the same 
PRS in other populations of different ancestry, because the underlying LD between variants is different, the 
PRS will not perform as well in new target populations [57, 91-93]. This is because in the new target popula-
tions, the PRS no longer appropriately corrects for the different correlation between the SNPs in the score. 
The more divergent the discovery and target populations, the worse a PRS will perform from one to the other. 
Because PRSs are normally built on European ancestry training datasets, their implementation in the clinic 
has the potential to systematically benefit individuals of European descent over people from other ancestries 
[57, 93].
The differences in effect size estimates due to LD differences between training and target populations are 
exacerbated in PRSs (vs GRSs) because they sum over all these effects on thousands or millions of variants, 
therefore, aggregating population differences relative to GRSs built on a much more limited number of ge-
nome-wide significant variants that are enriched in causal variants (or good tags for causal variants) that
tend to be shared, and have equivalent effects, between populations [93]. 
These issues with PRSs can also arise when the training and target populations are from the same broad 
ancestry but where the training set is derived from the aggregation of a very large collection of datasets in 
which there is residual substructure or population stratification [94, 95]. Population substructure occurs when 
there are systematic differences in allelic frequency between subgroups within the population. The recom-
mendation here might be to favour the use of more homogeneous large biobank populations as a training 
dataset over the use of large GWAS meta-analyses as the training dataset. This, however, will not always 
be an option and it remains a concern in the development and application of PRSs in the clinic.
Concerns regarding transferability of PRSs
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disease heterogeneity [78, 79]. These partitioned scores may
be able to identify subsets of individuals with type 2 diabetes
having different risks of complications [79]. Possible clinical
utility could additionally result from patient stratification for
correct treatment and therapy dosage according to the major
pathway predicted to be affected in the subset of patients, and
for the identification of participants for clinical trials [56].
However, whether patient stratification for treatment will
follow the success seen in monogenic diabetes remains a big
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Fig. 3 Population diversity in genetic studies of type 2 diabetes and
related glycaemic traits. The diagram shows a pictorial representation of
the world, with its populations and their admixture represented by the
shaded people; the different colours represent differences in ancestral
admixture in different individuals. The main areas that benefit from
increasing population diversity in genetic studies are shown; these
include: trait-associated locus discovery; portability of signals across
populations; improving fine-mapping resolution; and development of a
more equitable precision medicine approach (e.g. through development
of GRSs or PRSs based onmulti-ancestral population data). This figure is
available as part of a downloadable slideset
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Conclusions
Over the last few years, diabetes and glycaemic trait GWAS
have included data with broader genetic diversity. This has led
to novel locus discovery, improved understanding of the
genetic architecture of diabetes and related glycaemic traits
across ancestries, improved fine-mapping resolution and
resulted in the development of GRSs that better capture
disease risk across populations (Fig. 3). Nevertheless, efforts
to increase global representation in genetic studies need to be
intensified to fully capture the aetiology of type 2 diabetes and
associated traits across the world, specifically in under-
represented populations, wherein the rise in diabetes preva-
lence is predicted to be especially notable in the forthcoming
years. There is a need to increase representation of different
ancestries in regulatory annotation efforts (e.g. generation of
expression quantitative trait [eQTL] data), to enable ancestry-
specific effects to be interpreted within local context. These
annotations have been instrumental in pinpointing causal
genes at GWAS loci [8] and are key in the journey from
genetic association to improved mechanistic insight.
The opportunities afforded by increasing diversity in genet-
ic studies of type 2 diabetes and related glycaemic traits are
undisputed. However, it is important to stress that the human
population is a continuum with no discrete boundaries
between groups, whether these are defined on the basis of
self-reported ethnicity or on the basis of genetically defined
ancestry. It is critical therefore, that we move away from
describing ancestry based on large continental labels and
acknowledge the finer-grained population-level genetic diver-
sity that reflects population history, migration and admixture.
Though there are practical reasons for grouping individuals
into clusters, in the end we are all admixed with different
degrees of contribution from various ancestral groups.
Though significant progress has been made, there remain
methodological challenges relating to allelic, phenotypic and
environmental heterogeneity. Most importantly, there are signif-
icant ethical, societal and cultural challenges still to overcome.
Given historical malpractices [80, 81], some communities have
naturally become disengaged and suspicious of genetic and
genomic efforts. Going forward, engaging with global and indig-
enous populations needs to be done sensitively and be respectful
of local cultures. Ownership of the research agenda and leader-
ship has to be held by those within those communities [82]. An
example is the H3A initiative, which set out to empower African
researchers to lead and take centre stage in genomic research
[83–85]. A considered balance needs to be achieved between
the desire to rapidly, publicly, share data globally for the
advancement of science and the need to consider critical aspects
of indigenous governance policies for self-determination with
respect to genomics issues [81]. In addition, equity of access,
and ability to use the samples collected and analyse the data
generated are important to help level out the playing field [86].
It must also be recognised that for global collaborations
between high-income and low- and middle-income countries
to be effective, one must take the view of the importance of
long-term deliverables rather than focus exclusively on short-
term gains. Investment must be made in infrastructure, in
building local research capacity and leadership, and in creat-
ing opportunities for ‘brain gain’. New initiatives that perhaps
focus on bringing experts in from outside for periods of time
to conduct research locally, collaborate, train and build local
capacity instead of taking local researchers or samples out
may avoid so-called ‘helicopter’ or ‘parachute’ science [80,
81]. However, it must be recognised that progress will take
time and will need to leverage outside funding to generate
investment from local governments. In sum, the road ahead
may be long and arduous but it will surely lead us to a better
world.
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